Combined Central and Peripheral Demyelination Disease
Conditions
Keywords
CCPD, clinical features, antibody
Brief summary
The investigators conduct this study to clarify the clinical features and to evaluate the prevalence of anti-nodal/paranodal antibodies of patients with combined central and peripheral demyelination (CCPD) .
Detailed description
The investigators will review the clinical manifestation, laboratory test results, electrophysiological examination and neuroimaging findings of patients with CCPD. And we will detect antibodies to aquaporin 4(AQP4), myelin oligodendrocyte glycoprotein (MOG), neurofascin-155 (Nfasc155), neurofascin-186 (Nfasc186), and myelin-associated glycoprotein (MAG) in patients with CCPD.
Interventions
None listed
Sponsors
Xuanwu Hospital, Beijing
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. T2 high-signal intensity lesions in the brain or spinal cord on MRI, or visual-evoked potentials(VEPs) abnormalities. 2. conduction delay, conduction block, temporal dispersion or F-wave abnormalities, suggesting peripheral demyelinating neuropathy regarding nerve conduction studies (NCS).
Exclusion criteria
1. infectious diseases(e.g., human T lymphocyte trophic virus type1-associated myelopathy, syphilis, neuroborreliosis, HIV infection or progressive multifocal leukoencephalopathy) 2. pre-existing inflammatory diseases (e.g., sarcoidosis, Behçet's disease, Sjögren's syndrome, vasculitis or other collagen diseases) 3. mitochondrial disease 4. metabolic/toxic diseases (e.g., vitamin deficiency, amyloidosis, chronic alcoholism, diabetes mellitus or subacute myelo-opticoneuropathy due to clioquinol intoxication 5. cervical spondylotic myelopathy 6. syringomyelia 7. spinocerebellar degeneration 8. multiple myeloma, other tumors 9. inherited diseases (e.g., leucodystrophies) 10. cerebrovascular disease 11. non-specific lesions on T2-weighted MRI (e.g., leucoaraiosis).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Laboratory findings of nodal/paranodal antibodies in blood of patients with CCPD | Day 1 post-gathering information of patients in hospital medical record system | These antibody including anti-neurofascin 155(NF155) et.al. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Demographic characteristics | Day 1 post-gathering information of patients in hospital medical record system | The demographic characteristics of patients with CCPD such as age,sex,and et.al |
| Neurological symptoms and signs | Day 1 post-gathering information of patients in hospital medical record system | The neurological symptoms and signs of patients with CCPD |
| Laboratory findings of blood and cerebrospinal fluid | Day 1 post-gathering information of patients in hospital medical record system | Laboratory findings of blood and cerebrospinal fluid of patients with CCPD such as C reactive protein et.al in blood and protein et.al in cerebrospinal fluid |
| Neuroimaging and VEPs findings | Day 1 post-gathering information of patients in hospital medical record system | Neuroimaging and VEPs findings of patients with CCPD |
| Nerve conduction study findings | Day 1 post-gathering information of patients in hospital medical record system | Nerve conduction study findings of patients with CCPD |
Contacts
Primary ContactJunwei Hao, MD,PhD
Backup ContactXiaodan Hou, MD
Outcome results
None listed